Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
June 4, 2001
- DIAGNOSTIC NEWS IN BRIEF -2-
May 28, 2001
- Current Status of Antibody Drug Development Reported: PMSRL Seminar
May 28, 2001
- ABBREVIATION OF THE WEEK
May 28, 2001
- BUSINESS NEWS IN BRIEF -1-
May 28, 2001
- Terumo: Consolidated Sales Increase for 7 Consecutive Years to \176 Bil.
May 28, 2001
- BUSINESS NEWS IN BRIEF -2-
May 28, 2001
- NEDO to Develop Gene Diagnosis System for Cancer, Therapeutic Systems for Cardiac Disease
May 28, 2001
- CDFS Recommends 7 Ingredients Including Montelukast, Zolmitriptan for Approval
May 28, 2001
- Protecting, Fostering Innovation Must Be Fundamental Part of Healthcare System: Dr McKinnell of PhRMA
May 28, 2001
- BUSINESS NEWS IN BRIEF -3-
May 28, 2001
- 5 of 7 Firms Including Takeda, Eisai, Daiichi Report Record-high Profits
May 28, 2001
- Classification of Existing Drugs Proposed at Chuikyo
May 28, 2001
- Mitsubishi-Tokyo: Sales Total \84.2 Bil.,Attributable to Growth of Mainstays
May 28, 2001
- Industry Opposes Ministry Data on Prices of Original Products and Generics
May 28, 2001
- Mitsubishi Chemical: Pharmaceutical Sales Top \127.4 Bil.
May 28, 2001
- New Orphan Drugs, Medical Device Announced
May 28, 2001
- WORLD NEWS IN BRIEF
May 28, 2001
- Kyowa Hakko: Drug Sales Down to \141.4 Bil. Due to Suspension of Acenalin Shipment
May 28, 2001
- Industry Must Accept Price Reduction for Long-listed Products: Health Minister
May 28, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…